KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) EBT (2023 - 2025)

Biocryst Pharmaceuticals' EBT history spans 9 years, with the latest figure at $248.0 million for Q4 2025.

  • For Q4 2025, EBT rose 1054.24% year-over-year to $248.0 million; the TTM value through Dec 2025 reached $267.4 million, up 407.51%, while the annual FY2025 figure was $267.4 million, 407.51% up from the prior year.
  • EBT reached $248.0 million in Q4 2025 per BCRX's latest filing, up from $12.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $248.0 million in Q4 2025 to a low of -$170.4 million in Q4 2023.
  • Average EBT over 3 years is $1.1 million, with a median of -$12.5 million recorded in 2024.
  • Peak YoY movement for EBT: soared 84.75% in 2024, then soared 1054.24% in 2025.
  • A 3-year view of EBT shows it stood at -$170.4 million in 2023, then skyrocketed by 84.75% to -$26.0 million in 2024, then skyrocketed by 1054.24% to $248.0 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's EBT are $248.0 million (Q4 2025), $12.1 million (Q3 2025), and $6.5 million (Q2 2025).